%0 Journal Article
%T Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.
%A Zhang L
%A Deeb G
%A Deeb KK
%A Vale C
%A Peker Barclift D
%A Papadantonakis N
%J Cancers (Basel)
%V 16
%N 8
%D 2024 Apr 15
%M 38672585
%F 6.575
%R 10.3390/cancers16081503
%X Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes.